Alaunos Therapeutics, Inc. — Form SCHEDULE 13D
Filed October 15, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Three Fairmount entities (Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and Fairmount Healthcare Co-Invest VII L.P.) signed a joint filing agreement on October 15, 2026, to file a Schedule 13D regarding Alaunos Therapeutics common stock. The document itself contains no disclosure of shareholding percentage, share count, or dollar amount of the position. This is a procedural filing announcing coordinated disclosure; the substantive 13D disclosing actual holdings and intent is not attached to this excerpt.
Why this rating
Joint filing agreement is procedural boilerplate with no material terms disclosed. Significance depends entirely on 13D content (holdings %, intent) not provided here. Filing alone is routine SEC compliance.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.